India's ruling on Novartis has sparked a lot of criticism in the US, and may lead to a reduction in foreign investment in Indian pharma companies. The decision may also prompt the US to protect its own turf when it comes to generic manufacturers. Peter Pitts, president and co-founder, Centre for Medicine in Public Interest, says that the ruling shows that India doesn't understand the concept of pharmaceutical innovation, warning that it could drive innovation out of the country.
